Comparative assessment of the antioxidant and nephroprotective effects of melatonin and methylethylpyridinol hydrochloride in diabetic nephropathy

Goal: one of the most common complications of diabetes mellitus is diabetic nephropathy (DN). The central role in the pathogenesis of this complication plays the oxidative stress mediated by chronic hyperglycemia. Despite the existing methods of treatment, DN patients are characterized by a high risk of developing end-stage renal failure. In this regard, we carried out a comparative assessment of the therapeutic efficacy of combined treatment with melatonin and methylethylpiridinol hydrochloride that has antioxidant potential. Methods: the study involved 90 people with DN developing on the background of type 2 diabetes mellitus. The patients were divided into 3 groups of 30 people. The first group of patients was on basic treatment; the second group of the participants received 2 mg of melatonin in addition to the basic therapy; the third group of patients, in addition to the basic therapy, received 10 mg of methylethylpyridinol hydrochloride. The control group consisted of 65 healthy individuals with normal indicators of general and biochemical blood tests. In the course of the work, the analysis of clinical and biochemical indicators of the pathology development, parameters of biochemiluminescence (BCL), and the activity of superoxide dismutase (SOD) and catalase in DN patients of all three groups was carried out. Results: the results of the study showed that the level of glycaemia, concentration of creatinine and postprandial glucose were significantly decreased in all three groups of patients. The combined therapy with melatonin and methylethylpiridinol hydrochloride had a more significant effect on the SOD activity as compared with the basic treatment. In addition, the addition of melatonin to the treatment regimen led to a more significant decrease in the level of glycaemia and proteinuria, as well as a change in BCL parameters and catalase activity in the direction of their values in the control group. Conclusion: our results are probably associated with the high biological activity of melatonin, which has a regulatory activity in relation to carbohydrate metabolism and the functioning of the antioxidant system.

диабетическая нефропатия, мелатонин, метилэтилпиридинол, окислительный стресс, супероксиддисмутаза, каталаза, diabetic nephropathy, melatonin, methylethylpiridinol, oxidative stress, superoxide dismutase, catalase

1. Tesch G.H. Diabetic nephropathy - is this an immune disorder? Clin Sci (Lond). 2017; 131(16): 2183-2199. DOI: 10.1042/CS20160636.

2. Sifuentes-Franco S., Padilla-Tejeda D.E., Carrillo-Ibarra S., et al. Oxidative Stress, Apoptosis, and Mitochondrial Function in Diabetic Nephropathy. International Journal of Endocrinology. 2018; 2018(2): 1-13. DOI: 10.1155/2018/1875870.

3. Miranda-Díaz A.G., Pazarín-Villaseñor L., Yanowsky-Escatell F.G., et al. Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. J Diabetes Res. 2016; 2016: 7047238. DOI: 10.1155/2016/7047238.

4. Sanajou D., Haghjo A.G., Argani H., et al. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Eur J Pharmacol. 2018; 833: 158-164. DOI: 10.1016/j.ejphar.2018.06.001.

5. Sagoo M.K., Gnudi L. Diabetic nephropathy: Is there a role for oxidative stress? Free Radic Biol Med. 2018; 116: 50-63. DOI: 10.1016/j.freeradbiomed.2017.12.040.

6. Mesquita A., Weinberger M., Silva A., et al. Caloric restriction or catalase inactivation extends yeast chronological lifespan by inducing H2O2 and superoxide dismutase activity. PNAS. 2010; 107(34): 15123-15128. DOI: 10.1073/pnas.1004432107.

7. Voelker J., Berg P.H., Sheetz M., et al. Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy. JASN. 2017; 28(3): 953-962. DOI: 10.1681/ASN.2015111230.

8. Волчегорский И.А., Мирошниченко И.Ю., Рассохина Л.М и соавт. Анксиолитическое и антидепрессивное действие эмоксипина, реамберина и мексидола при экспериментальном сахарном диабете. Журнал неврологии и психиатрии. 2017; 5: 52-57. DOI: 10.17116/jnevro20171175152-57.

9. Агарков А.А., Попова Т.Н., Матасова Л.В., и соавт. Оценка степени фрагментации ДНК, активности аконитатгидратазы и уровня цитрата при сахарном диабете 2 типа у крыс и введении мелатонина. Российский медико-биологический вестник им. академика И.П. Павлова. 2012; 20(3): 21-26. DOI: 10.17816/PAVLOVJ2012321-26.

10. Горбенко М.В., Попова Т.Н., Шульгин К.К., и соавт. Влияние мелаксена и вальдоксана на активность глутатионовой антиоксидантной системы и НАДФН-генерирующих ферментов в сердце крыс при экспериментальном гипертиреозе. 2013; 76(10): 12-15. DOI: 10.30906/0869-2092-2013-76-10-12-15.

11. Попов С.С., Пашков А.Н., Золоедов В.И., и соавт. Применение мелатонина в комбинированной терапии при лечении лекарственного гепатита. Клиническая медицина. 2013; 91(3): 50-53.

12. Piskarev I.M., Trofimova S.V., Ivanova I.P., et al. Investigation of the level of free-radical processes in substrates and biological samples using induced chemiluminescence. Biophysics. 2015; 60: 400-408. DOI: 10.1134/S0006350915030148.

13. Nishikimi M., Rao N.A. Yagi, K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulphate and molecular oxygen. Biochem. Biophys. Res. Co. 1972; 46(2): 849-864. DOI: 10.1016/s0006-291x(72)80218-3.

14. Góth, L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta. 1991; 196(2-3): 143-151. DOI: 10.1016/0009-8981(91)90067-m.

15. Zhao D., Yu Y., Shen Y, et al. Melatonin Synthesis and Function: Evolutionary History in Animals and Plants. Front Endocrinol. 2019; 10: 249. DOI: 10.3389/fendo.2019.00249.

16. Meng X., Li Y., Li S., et al. Dietary Sources and Bioactivities of Melatonin. Nutrients. 2017; 9(4): E367. DOI: 10.3390/nu9040367.

17. Lindblom R., Higgins G., Coughlan M., et al. Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy. Rev Diabet Stud. 2015; 12(1-2): 134-156. DOI: 10.1900/RDS.2015.12.134.

18. Stacchiotti A., Favero G., Giugno L., et al. Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: Protective role of melatonin. PLoS One. 2014; 9(10): e111141. DOI: 10.1371/journal.pone.0111141.

19. Giribabu N., Rao P.V. Kumar K.P., et al. Aqueous Extract of Phyllanthus niruri Leaves Displays In Vitro Antioxidant Activity and Prevents the Elevation of Oxidative Stress in the Kidney of Streptozotocin-Induced Diabetic Male Rats. Evid Based Complement Alternat Med. 2014; 2014: 834815. DOI: 10.1155/2014/834815.

20. Xie R., Zhang H., Wang X-Z., et al. The protective effect of betulinic acid (BA) diabetic nephropathy on streptozotocin (STZ)-induced diabetic rats. Food Funct. 2017; 8(1): 299-306. DOI: 10.1039/c6fo01601d.

21. Peresypkina A, Pazhinsky A, Pokrovskii M, et al. Correction of Experimental Retinal Ischemia by l-Isomer of Ethylmethylhydroxypyridine Malate. Antioxidants (Basel). 2019; 8(2): E34. DOI: 10.3390/antiox8020034.

22. Lowes D.A., Webster N.R., Murphy M.P., et al. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth. 2013; 110(3): 472-480. DOI: 10.1093/bja/aes577.

23. Fernando S., Rombauts L. Melatonin: shedding light on infertility? - A review of the recent literature. J Ovarian Res. 2014; 7: 98. DOI: 10.1186/s13048-014-0098-y.

24. Korkmaz A., Reiter R.J., Topal T., et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med. 2009; 15(1-2): 43-50. DOI: 10.2119/molmed.2008.00117.